GLPwatch

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

NCT04667377 · Completed

Last updated 2026-05-28

This clinical trial is testing different doses of the medication BI 456906 in adults with overweight or obesity to see how it affects weight loss over 46 weeks.

Status Completed The study has finished.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 387 people
Who can join Ages 18–75 · all sexes
Timeline Started 2021-03 · est. completion 2022-10
Where 43 sites · Australia, Belgium, Canada, China, Germany, Netherlands, New Zealand, Poland, South Korea, Sweden, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT04667377 ↗

Description as written by the study sponsor.

This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps people lose weight. Participants are put into 5 groups by chance. 4 groups get different doses of BI 456906. The fifth group gets placebo. Participants get BI 456906 or placebo as injections under the skin once a week. Placebo injections look like BI 456906 injections but do not contain any medicine. Participants are in the study for about a year. During this time, there are about 20 in-person visits to the study site. At the study site visits, doctors measure participants' body weight. Results are compared between the BI 456906 groups and the placebo group. The doctors also regularly check the general health of the participants.

Treatments tested

Main thing measuredPercentage Change in Body Weight From Baseline to Week 46
SponsorBoehringer Ingelheim
Conditions studiedObesity
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04667377 ↗